• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表面处理的 AN69 膜是否可以在无抗凝的 CRRT 中延长滤器的使用寿命?

Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?

机构信息

Department of Intensive Care Medicine, University Hospital of the Catholic University Leuven, Herestraat 49, 3000, Leuven, Belgium.

出版信息

Intensive Care Med. 2012 Nov;38(11):1818-25. doi: 10.1007/s00134-012-2633-x. Epub 2012 Jul 7.

DOI:10.1007/s00134-012-2633-x
PMID:22773036
Abstract

PURPOSE

The need for continuous anticoagulation remains a significant drawback in continuous renal replacement therapy (CRRT), especially in patients with increased bleeding risk. Polyethyleneimine treatment of the AN69 membrane (AN69ST) reduces thrombogenicity through decreased contact activation and promotion of heparin binding. The aim of this study is to evaluate whether this membrane prolongs filter survival in CRRT without anticoagulation.

METHODS

A single-center, prospective, randomized, double-blind controlled trial with cross-over design comparing filter survival with the AN69ST membrane and the original AN69 membrane in 39 patients treated with continuous venovenous hemofiltraton (CVVH) without additional heparin.

RESULTS

Filter survival with the AN69ST membrane (n = 75) was 14.2 ± 8.2 h, which is not significantly different from the 13.3 ± 10.3 h for the original AN69 membrane (n = 76; p = 0.59). Limiting the analysis to those treatments that were interrupted for filter clotting yielded similar results: 14.4 ± 8.2 h for the AN69 ST membrane (n = 62) versus 14.1 ± 7.5 h for the original AN69 membrane (n = 56) (p = 0.93).

CONCLUSIONS

Compared with the original AN69 membrane, the surface-treated AN69ST membrane does not prolong filter survival during CVVH without systemic anticoagulation and with the CRRT settings used in this study.

摘要

目的

在连续肾脏替代治疗(CRRT)中,持续抗凝仍然是一个显著的缺点,尤其是在出血风险增加的患者中。聚亚乙基亚胺处理的 AN69 膜(AN69ST)通过减少接触激活和促进肝素结合来降低血栓形成性。本研究旨在评估在无抗凝的情况下,这种膜是否能延长 CRRT 中的过滤器寿命。

方法

一项单中心、前瞻性、随机、双盲对照试验,采用交叉设计,比较了在 39 例接受连续静脉-静脉血液滤过(CVVH)治疗的患者中,使用 AN69ST 膜和原始 AN69 膜的过滤器寿命,且均未额外使用肝素。

结果

AN69ST 膜(n = 75)的过滤器寿命为 14.2 ± 8.2 h,与原始 AN69 膜(n = 76;p = 0.59)的 13.3 ± 10.3 h 无显著差异。将分析仅限于因过滤器堵塞而中断的治疗,得到了类似的结果:AN69 ST 膜(n = 62)的 14.4 ± 8.2 h 与原始 AN69 膜(n = 56)的 14.1 ± 7.5 h 无显著差异(p = 0.93)。

结论

与原始 AN69 膜相比,在无全身抗凝且使用本研究中 CRRT 设置的情况下,表面处理的 AN69ST 膜不能延长 CVVH 期间的过滤器寿命。

相似文献

1
Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?表面处理的 AN69 膜是否可以在无抗凝的 CRRT 中延长滤器的使用寿命?
Intensive Care Med. 2012 Nov;38(11):1818-25. doi: 10.1007/s00134-012-2633-x. Epub 2012 Jul 7.
2
Polyethyleneimine-treated polyacrylonitrile membrane hemofilter for critically ill patients receiving anticoagulant-free prolonged intermittent renal replacement therapy: a single-center, prospective, self-controlled pilot study.用于接受无抗凝剂延长间歇性肾脏替代治疗的危重症患者的聚乙烯亚胺处理的聚丙烯腈膜血液滤过器:一项单中心、前瞻性、自身对照的试点研究。
BMC Nephrol. 2017 Jun 30;18(1):208. doi: 10.1186/s12882-017-0627-1.
3
[The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding].[AN69 ST膜对出血高风险患者在无抗凝的连续性肾脏替代治疗中滤器使用寿命的影响]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 May;27(5):343-8. doi: 10.3760/cma.j.issn.2095-4352.2015.05.005.
4
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.使用肝素涂层聚丙烯腈膜进行血液透析时的最佳抗凝策略。
Nephrol Dial Transplant. 2003 Oct;18(10):2097-104. doi: 10.1093/ndt/gfg272.
5
The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.低剂量肝素在血液透析中的临床评估:一项使用肝素涂层AN69 ST膜的前瞻性研究。
Nephrol Dial Transplant. 2008 Jun;23(6):2003-9. doi: 10.1093/ndt/gfm888. Epub 2007 Dec 21.
6
The effect of the AN69 ST100 versus oXiris membrane on filter life during CRRT for non-anticoagulated liver failure patients.对于非抗凝的肝衰竭患者,在连续性肾脏替代治疗(CRRT)期间,AN69 ST100膜与oXiris膜对滤器寿命的影响。
Int J Artif Organs. 2023 Apr;46(4):209-214. doi: 10.1177/03913988231155253. Epub 2023 Mar 9.
7
Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.非药物干预措施预防连续性肾脏替代治疗中体外循环凝血。
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD013330. doi: 10.1002/14651858.CD013330.pub2.
8
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.持续静静脉血液滤过和持续静静脉血液透析对万古霉素清除率的影响因素。
Am J Kidney Dis. 1998 Jun;31(6):1019-27. doi: 10.1053/ajkd.1998.v31.pm9631848.
9
Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.头孢吡肟与连续性肾脏替代治疗(CRRT):两种CRRT膜的体外通透性及4例危重症患者的药代动力学
Clin Ther. 2005 May;27(5):599-608. doi: 10.1016/j.clinthera.2005.05.004.
10
Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration.肝素结合型AN69 ST血液透析膜的评估:II. 无肝素给药的临床研究。
ASAIO J. 2005 Jul-Aug;51(4):348-51. doi: 10.1097/01.mat.0000169121.09075.53.

引用本文的文献

1
How to safeguard the continuous renal replacement therapy circuit: a narrative review.如何保障连续性肾脏替代治疗回路:一篇叙述性综述
Front Med (Lausanne). 2024 Aug 21;11:1442065. doi: 10.3389/fmed.2024.1442065. eCollection 2024.
2
Solute Clearance Evaluation and Filter Clotting Prediction in Continuous Renal Replacement Therapy.连续性肾脏替代治疗中溶质清除评估与滤器凝血预测
J Clin Med. 2023 Dec 15;12(24):7703. doi: 10.3390/jcm12247703.
3
Continuous Renal Replacement Therapy in Critically Ill Children.危重症儿童的连续性肾脏替代治疗

本文引用的文献

1
Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60).无肝素血液透析:两种透析膜(AN69ST和聚砜F60)的随机对照交叉研究
Int J Artif Organs. 2011 Dec;34(12):1165-71. doi: 10.5301/ijao.5000033.
2
A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F×8).与传统聚砜膜(F×8)相比,肝素涂层透析器(AN69 ST)并不能减少血液透析过程中的凝血。
Blood Purif. 2011;32(3):151-5. doi: 10.1159/000325227. Epub 2011 Jun 10.
3
Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect.
Turk Arch Pediatr. 2022 Sep;57(5):489-497. doi: 10.5152/TurkArchPediatr.2022.22082.
4
Effect of Dynamic Circuit Pressures Monitoring on the Lifespan of Extracorporeal Circuit and the Efficiency of Solute Removal During Continuous Renal Replacement Therapy.动态回路压力监测对连续肾脏替代治疗期间体外循环寿命及溶质清除效率的影响
Front Med (Lausanne). 2021 Sep 23;8:621921. doi: 10.3389/fmed.2021.621921. eCollection 2021.
5
Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.非药物干预措施预防连续性肾脏替代治疗中体外循环凝血。
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD013330. doi: 10.1002/14651858.CD013330.pub2.
6
Antithrombotic properties of hemofilter coated with polymer having a hydrophilic blood-contacting layer.具有亲水性血液接触层的聚合物涂层血液滤过器的抗血栓特性
Int J Artif Organs. 2019 Feb;42(2):88-94. doi: 10.1177/0391398818815480. Epub 2018 Nov 29.
7
Micro-computed tomography for the quantification of blocked fibers in hemodialyzers.使用微计算机断层扫描定量评估血液透析器中的纤维堵塞。
Sci Rep. 2018 Feb 8;8(1):2677. doi: 10.1038/s41598-018-20898-w.
8
Polyethyleneimine-treated polyacrylonitrile membrane hemofilter for critically ill patients receiving anticoagulant-free prolonged intermittent renal replacement therapy: a single-center, prospective, self-controlled pilot study.用于接受无抗凝剂延长间歇性肾脏替代治疗的危重症患者的聚乙烯亚胺处理的聚丙烯腈膜血液滤过器:一项单中心、前瞻性、自身对照的试点研究。
BMC Nephrol. 2017 Jun 30;18(1):208. doi: 10.1186/s12882-017-0627-1.
9
Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis.连续肾脏替代治疗(CRRT)中与滤器寿命相关的非抗凝因素:一项系统评价和荟萃分析。
BMC Nephrol. 2017 Feb 20;18(1):69. doi: 10.1186/s12882-017-0445-5.
10
Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD).成人及儿童重症监护中的肾脏替代治疗:法国重症监护学会(SRLF)联合法国麻醉重症监护学会(SFAR)、法国儿童重症监护急救小组(GFRUP)以及法国透析学会(SFD)专家小组的建议
Ann Intensive Care. 2015 Dec;5(1):58. doi: 10.1186/s13613-015-0093-5. Epub 2015 Dec 30.
评估三种不同的方法来防止透析器凝血而不引起全身抗凝作用。
Artif Organs. 2011 Jan;35(1):83-8. doi: 10.1111/j.1525-1594.2010.01038.x.
4
Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill?在危重症患者的持续肾脏替代治疗中,回路使用寿命能否作为一项质量指标?
Int J Artif Organs. 2010 Mar;33(3):139-46. doi: 10.1177/039139881003300302.
5
Citrate anticoagulation for continuous renal replacement therapy in the critically ill.枸橼酸抗凝在危重症连续性肾脏替代治疗中的应用。
Blood Purif. 2010;29(2):191-6. doi: 10.1159/000245646. Epub 2010 Jan 8.
6
Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy.用于PrismaFlex持续肾脏替代治疗的局部枸橼酸盐抗凝法。
Ann Pharmacother. 2009 Sep;43(9):1419-25. doi: 10.1345/aph.1M182. Epub 2009 Aug 18.
7
Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.表达组织因子的单核细胞通过一种凝血酶激活的纤溶抑制因子介导的机制抑制纤维蛋白溶解,并使血栓对肝素产生抵抗。
Haematologica. 2009 Jun;94(6):819-26. doi: 10.3324/haematol.2008.000042. Epub 2009 Apr 18.
8
The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.低剂量肝素在血液透析中的临床评估:一项使用肝素涂层AN69 ST膜的前瞻性研究。
Nephrol Dial Transplant. 2008 Jun;23(6):2003-9. doi: 10.1093/ndt/gfm888. Epub 2007 Dec 21.
9
Clinical review: Patency of the circuit in continuous renal replacement therapy.临床综述:连续性肾脏替代治疗中血管通路的通畅性
Crit Care. 2007;11(4):218. doi: 10.1186/cc5937.
10
Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.肝素涂层聚丙烯腈膜与局部枸橼酸盐抗凝:对有出血风险患者的两种抗凝策略的前瞻性随机研究。
Am J Kidney Dis. 2007 May;49(5):642-9. doi: 10.1053/j.ajkd.2007.02.001.